Merck, Moderna Stocks Soar After Melanoma Trial Success
Share
Shares of Moderna and Merck soared on Wednesday morning after a study showed that a vaccine they produced had promising results when it comes to fighting skin cancer. A late-stage trial showed that the mRNA vaccine helped reduce the recurrence of melanoma. Sam Fazeli of Bloomberg Intelligence has more.
More from Australia
Resurgent inflation pressures test key Australian consumer shares
The digital cart rush redefining Australian retail profit pools
Trans-Tasman insurers battle contract churn while defending profit margins
Capital battles heat up as takeover offers challenge listed housing operators
The equities fueling the next infrastructure supercycle
Crypto networks collide with sanctions in a fight for financial access